Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of UMC119-06-05 in Elderly Subjects With Frailty Syndrome
NCT04914403Phase 1Unknown
- Sponsor
- Meridigen Biotech Co., Ltd.
- Start
- Sep 2021
- Primary completion
- Dec 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of UMC119-06-05 in frailty syndrome (2 cohorts), sponsored by Meridigen Biotech Co., Ltd. Primary endpoint: Incidence and frequency of adverse events at 3 months. Status: unknown.
02
Drugs
UMC119-06-05
03
Conditions
frailty syndrome
Beyond the preview
Go deeper on NCT04914403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04914403.